Search results
Results from the WOW.Com Content Network
Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. [7] [8] It is considered to be highly effective in dogs, and has been established as safe for at least short-term use.
Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...
Bravecto 1-Month was approved by the FDA in November 2024 for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for one month in dogs and puppies eigjht weeks of age and older, and weighing 4.4 pounds (2.0 kg) or greater.
Sulfadimethoxine (or sulphadimethoxine, trade names Di-Methox or Albon) is a long-lasting sulfonamide antimicrobial medication used in veterinary medicine. It is used to treat many infections, including respiratory, urinary tract, enteric, and soft tissue infections [3] and can be given as a standalone or combined with ormetoprim to broaden the target range. [2]
Deracoxib is a coxib class nonsteroidal anti-inflammatory drug (NSAID). [3] Like other NSAIDs, its effects are caused by inhibition of cyclooxygenase (COX) enzymes. [7] At the doses used to treat dogs, deracoxib causes greater inhibition of COX-2 than of COX-1, [3] but at doses twice those recommended for use in dogs, deracoxib significantly inhibits COX-1 as well.
This is because dogs spend a lot of time sniffing the ground, eating grass, and sometimes licking poop or urine they find outdoors. Here are five diseases you could catch from your dog , and how ...
Pimobendan is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); [1] [7] and for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. [1]
The approximate calculation for canine efficacy dose is between the range of 1.3 and 1.7 mg/kg, in conjunction with a methylcellulose suspending agent. Based on the calculations from the comparisons of binding affinity of grapiprant to the EP4 receptors of dogs, rats, and humans, the study of plasma and serum protein binding determinations, the ...